Immunovia

0,22 SEK

+5,16 %

Mindre end 1K følgere

IMMNOV

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Oversigt

Finansielt overblik og estimater

Ejerskab

Investorkonsensus

+5,16 %

-1,32 %

-18,84 %

-34,21 %

-38,31 %

-44,06 %

-97,50 %

-99,47 %

-97,90 %

Immunovia operates in the biotechnology industry and focuses on the development of diagnostic tools for the early detection of cancer. The company's research and development is focused on molecular diagnostics and its products are aimed at healthcare institutions and physicians. The business is global with a strong presence in Europe and North America. Immunovia was founded in 2007 and is headquartered in Lund.

Markedsværdi

150,68 mio. SEK

Aktieomsætning

790,93 t SEK

Omsætning

930 t

EBIT %

-11.764,52 %

P/E

-

Udbytteafkast, %

-

Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender

22.1

2026

Ekstraordinær generalforsamling '26

24.2

2026

Årsrapport '25

7.5

2026

Delårsrapport Q1'26

Alle

Selskabspræsentationer

Selskabsmeddelelser

ViserAlle indholdstyper

Pressemeddelelse22.12.2025, 07.30

Immunovia’s Analytical Validation Study of PancreaSure Published in Diagnostics

Selskabsmeddelelse17.12.2025, 16.20

NOTICE OF EXTRAORDINARY GENERAL MEETING IN IMMUNOVIA AB (PUBL)

Selskabsmeddelelse17.12.2025, 16.10

The Board of Directors of Immunovia proposes a reverse share split

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto

Følgere og notifikationer om fulgte virksomheder

Analytikerkommentarer og anbefalinger

Værktøj til at sammenligne aktier og andre populære værktøjer

Selskabsmeddelelse28.11.2025, 13.00

Change in number of shares and votes in Immunovia AB (publ)

Pressemeddelelse27.11.2025, 09.30

Carlsquare: Research update Immunovia, Q3 2025: US reimbursement in focus

Pressemeddelelse26.11.2025, 15.05

Immunovia receives final Medicare payment rate for PancreaSure™ test

Pressemeddelelse26.11.2025, 08.42

Carlsquare: First impression, Q3 2025: Successful rights issue to fuel launch and reimbursement progress

Selskabsmeddelelse26.11.2025, 07.30

Immunovia Publishes Interim Report for July-September 2025

Pressemeddelelse24.11.2025, 13.05

VERIFI Study Published in Peer-Reviewed Journal Current Oncology

Pressemeddelelse20.11.2025, 12.00

INVITATION TO IMMUNOVIA’S Q3 PRESENTATION

Selskabsmeddelelse29.10.2025, 17.30

Immunovia carries out a directed issue of shares to guarantors in connection with the completed rights issue

Pressemeddelelse27.10.2025, 13.00

Immunovia's PancreaSure Study Published in Leading Journal Gastroenterology

Pressemeddelelse27.10.2025, 07.00

PancreaSure clinical validation data to be presented at the American Gastroenterology Annual Scientific Meeting

Selskabsmeddelelse23.10.2025, 14.00

Immunovia announces outcome of the rights issue

Selskabsmeddelelse16.10.2025, 06.30

The last day of trading in subscription rights in Immunovia's rights issue

Pressemeddelelse13.10.2025, 12.05

Immunovia’s Laboratory Receives CAP Accreditation

Pressemeddelelse10.10.2025, 06.30

Immunovia highlights PancreaSure presentation at Inherited Gastrointestinal Cancers Meeting

Selskabsmeddelelse3.10.2025, 13.00

Immunovia publishes information document regarding rights issue

Selskabsmeddelelse29.9.2025, 12.15

Bulletin from the extraordinary general meeting in Immunovia AB (publ)

Pressemeddelelse26.9.2025, 05.40

Carlsquare: Research update Immunovia: PancreaSure launch in the US is underway

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.